Abstract
in general practice. A decision-analysis model was constructed for health effects of the program: averted pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy, infertility, and neonatal pneumonia (major outcomes averted). We explicitly included reinfection due to failed partner referral in the model. Cost-effectiveness estimates included direct and indirect costs. At current test costs – of US$ 17 for ligase chain reaction test on urine – only screening women aged 15–19 years is cost saving. Net costs per cured woman and major outcome averted for screening women younger than 30 are below US$ 150 and US$ 410, respectively. These results are sensitive to reinfection. We conclude that explicit inclusion of reinfection is relevant for valid estimations of cost-effectiveness of screening for C. trachomatis. Based on cost-effectiveness considerations, we suggest implementation of a screening program in Amsterdam for sexually active women younger than 30 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
